Evidence map›Paper›PMID 33704077›Full record

ArticleJMIR diabetes2021

Evaluation of a Diabetes Remote Monitoring Program Facilitated by Connected Glucose Meters for Patients With Poorly Controlled Type 2 Diabetes: Randomized Crossover Trial.

Daniel J Amante, David M Harlan, Stephenie C Lemon, David D McManus, Oladapo O Olaitan, Sherry L Pagoto, Ben S Gerber, Michael J Thompson

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JMIR diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03124043 (Get In Touch Phase 2 - Evaluating a Diabetes Care Support Program Facilitated by Cellular-enabled Glucose Meters, a Randomized Crossover Trial), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03124043 nacompletednot on this map

Get In Touch Phase 2 - Evaluating a Diabetes Care Support Program Facilitated by Cellular-enabled Glucose Meters, a Randomized Crossover Trial

TypeinterventionalSponsorUniversity of Massachusetts, WorcesterRan2015 to 2017Enrolled120ConditionsDiabetes Mellitus, Type 2ArmsLivongo for Diabetes program
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Sustained Improvements in Readings in-Range Using an Advanced BluetoothDiabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Daniel J Amante *Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.ORCID https://orcid.org/0000-0003-1488-9624
David M HarlanDivision of Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States.ORCID https://orcid.org/0000-0002-6938-8109
Stephenie C LemonDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.ORCID https://orcid.org/0000-0003-3321-6070
David D McManusDivision of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States.ORCID https://orcid.org/0000-0002-9343-6203
Oladapo O OlaitanDepartment of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.ORCID https://orcid.org/0000-0002-1687-5720
Sherry L PagotoDepartment of Allied Health Sciences, Institute for Collaborations on Health, Interventions, and Policy, University of Connecticut, Storrs, CT, United States.ORCID https://orcid.org/0000-0002-2462-8797
Ben S GerberDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, United States.ORCID https://orcid.org/0000-0003-4367-6396
Michael J ThompsonDivision of Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States.ORCID https://orcid.org/0000-0002-5901-6918
University of Massachusetts Chan Medical School · USUniversity of Connecticut · USUniversity of Illinois Chicago · US

Funding

University of Massachusetts Center for Clinical and Translational ScienceKL2TR001455 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KIEFE, CATARINA I. · 2015 to 2024
$5.0M
NCATS NIH HHS KL2 TR001455
6 · The paper itself

Abstract

backgroundPatients with poorly controlled type 2 diabetes (T2D) experience increased morbidity, increased mortality, and higher cost of care. Self-monitoring of blood glucose (SMBG) is a critical component of diabetes self-management with established diabetes outcome benefits. Technological advancements in blood glucose meters, including cellular-connected devices that automatically upload SMBG data to secure cloud-based databases, allow for improved sharing and monitoring of SMBG data. Real-time monitoring of SMBG data presents opportunities to provide timely support to patients that is responsive to abnormal SMBG recordings. Such diabetes remote monitoring programs can provide patients with poorly controlled T2D additional support needed to improve critical outcomes.

objectiveTo evaluate 6 months of a diabetes remote monitoring program facilitated by cellular-connected glucose meter, access to a diabetes coach, and support responsive to abnormal blood glucose recordings greater than 400 mg/dL or below 50 mg/dL in adults with poorly controlled T2D.

methodsPatients (N=119) receiving care at a diabetes center of excellence participated in a two-arm, 12-month randomized crossover study. The intervention included a cellular-connected glucose meter and phone-based diabetes coaching provided by Livongo Health. The coach answered questions, assisted in goal setting, and provided support in response to abnormal glucose levels. One group received the intervention for 6 months before returning to usual care (IV/UC). The other group received usual care before enrolling in the intervention (UC/IV) for 6 months. Change in hemoglobin A

resultsImprovements in mean HbA

conclusionsPatients enrolled in the diabetes remote monitoring program intervention experienced improvements in HbA

trial registrationClinicalTrials.gov NCT03124043; https://clinicaltrials.gov/ct2/show/NCT03124043.

Indexed as

adultblood glucosediabetesremote monitoringself-monitoringsupporttelemedicinetype 2 diabetes

Identifiers

PMID33704077
PMCPMC7995078
OpenAlexW3120843836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.